Results 71 to 80 of about 13,449 (262)
Phenotyping patients with chronic obstructive pulmonary disease and heart failure
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher +12 more
wiley +1 more source
Background: Recent studies investigating the effects of fish oil on shocks administered by ICDs in patients with ventricular tachycardias produced inconclusive results.
Erfan Kohansal +5 more
doaj +1 more source
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch +8 more
wiley +1 more source
Subcutaneous implantable cardioverter defibrillators (S-ICDs) are increasingly implanted devices to prevent sudden cardiac death (SCD), whether as a primary or secondary prevention strategies especially in patients who are at risk of developing ...
Ohanian Antranik, Barake Hassan
doaj +1 more source
The Calculated Risk of Defibrillator Implantation
Clinical trials have convincingly demonstrated the efficacy of implantable cardioverter-defibrillators (ICD) for the prevention of sudden cardiac death in appropriately selected patients [(1–3)][1].
Marcus, Gregory M., Dewland, Thomas A.
openaire +2 more sources
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul +13 more
wiley +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi +9 more
wiley +1 more source
Driving restrictions in patients with implantable cardioverter defibrillators and pacemakers
Implantable cardioverter-defibrillators (ICDs) improve the survival in patients at risk of sudden cardiac death. However, these patients have an ongoing risk of sudden incapacitation that may cause harm to individuals and others when driving ...
Eiichi Watanabe +2 more
doaj +1 more source
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source

